Pro-Dex, Inc. (NASDAQ:PDEX – Get Free Report) shares crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $17.33 and traded as high as $17.90. Pro-Dex shares last traded at $17.60, with a volume of 1,436 shares.
Wall Street Analyst Weigh In
Separately, StockNews.com started coverage on Pro-Dex in a research note on Thursday. They set a “buy” rating for the company.
Pro-Dex Price Performance
Pro-Dex (NASDAQ:PDEX – Get Free Report) last issued its earnings results on Friday, October 13th. The medical instruments supplier reported $0.42 EPS for the quarter. Pro-Dex had a return on equity of 10.89% and a net margin of 6.56%. The company had revenue of $10.64 million during the quarter.
Hedge Funds Weigh In On Pro-Dex
A number of institutional investors have recently modified their holdings of the company. Punch & Associates Investment Management Inc. increased its stake in Pro-Dex by 8.1% during the 3rd quarter. Punch & Associates Investment Management Inc. now owns 69,610 shares of the medical instruments supplier’s stock valued at $1,093,000 after purchasing an additional 5,235 shares in the last quarter. Northern Trust Corp grew its position in shares of Pro-Dex by 4.1% during the 2nd quarter. Northern Trust Corp now owns 19,735 shares of the medical instruments supplier’s stock valued at $377,000 after acquiring an additional 776 shares during the period. UBS Group AG increased its holdings in Pro-Dex by 421.5% in the 1st quarter. UBS Group AG now owns 5,867 shares of the medical instruments supplier’s stock worth $96,000 after acquiring an additional 4,742 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Pro-Dex by 1.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 58,751 shares of the medical instruments supplier’s stock valued at $920,000 after purchasing an additional 625 shares during the period. Finally, Tower Research Capital LLC TRC lifted its stake in shares of Pro-Dex by 345.6% during the 3rd quarter. Tower Research Capital LLC TRC now owns 2,687 shares of the medical instruments supplier’s stock valued at $48,000 after buying an additional 2,084 shares in the last quarter. 14.78% of the stock is owned by institutional investors and hedge funds.
Pro-Dex Company Profile
Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.
- Five stocks we like better than Pro-Dex
- Investing in Construction Stocks
- 3 large caps with red hot RSIs with upside
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Johnson Controls International: Nothing but upside for investors
- How to Invest in Energy
- Unity Software’s resilient rebound post-earnings setback
Receive News & Ratings for Pro-Dex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pro-Dex and related companies with MarketBeat.com's FREE daily email newsletter.